Fatty Liver, Alcoholic: Clinical Trials

7 trials for Fatty Liver, Alcoholic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 not yet recruiting, 2 recruiting, 1 completed, 1 terminated. 4 Phase 2, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Not yet recruiting 2, Completed 1, Terminated 1
Not applicable1Recruiting 1
Phase 31Recruiting 1

Follow Fatty Liver, Alcoholic: new trials by email Literature Review of Fatty Liver, Alcoholic trials Research Report on Fatty Liver, Alcoholic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD
Phase 2Not yet recruitingRegeneron Pharmaceuticals1202026-12-092026-11-12
The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)
Palm Tocotrienol Rich Fraction (TRF), Refined, bleached, and deodorised (RBD) palm olein - Alcoholic Fatty Liver Disease
Phase 2Not yet recruitingUniversiti Kebangsaan Malaysia Medical Centre262026-05-022026-04-29
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Not applicableRecruitingPhenomen Pharma902025-06-192025-07-23
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
Encapsulated FMT, Placebo - Liver Cirrhosis
Phase 3RecruitingKing's College London3002023-06-212026-02-24
Digoxin In Treatment of Alcohol Associated Hepatitis
Intravenous digoxin - Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Phase 2TerminatedYale University232021-10-082026-09-29
Fatty Liver Disease Collaborative Research in China
Fatty Liver, Fatty Liver, Alcoholic
UnknownFatty Liver and Alcoholic Liver Disease Study Group, China30002015-07-012015-08-05
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
Placebo /bid P.O, MG-1, MG-2 : MG1000mg, Placebo /bid P.O - Alcoholic Fatty Liver Disease, Alcoholic Hepatitis
Phase 2CompletedPharmaKing902010-11-012015-04-29

Narrower conditions

Non-alcoholic Fatty Liver Disease (4)  ·  Fatty Liver (3)  ·  Liver Diseases (3)  ·  Fibrosis (2)  ·  Hepatitis, Alcoholic (2)  ·  Liver Cirrhosis (2)  ·  Acute-On-Chronic Liver Failure (1)  ·  Alcohol-Induced Disorders (1)  ·  Alcoholism (1)  ·  Chemical and Drug Induced Liver Injury (1)  ·  End Stage Liver Disease (1)  ·  Hepatic Encephalopathy (1)  ·  Hepatic Insufficiency (1)  ·  Hepatitis (1)

Broader conditions

Alcohol-Related Disorders (7)  ·  Chemically-Induced Disorders (7)  ·  Digestive System Diseases (7)  ·  Substance-Related Disorders (7)  ·  Alcohol-Induced Disorders (6)  ·  Liver Diseases, Alcoholic (6)  ·  Fatty Liver (4)  ·  Liver Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Hepatitis (2)  ·  Liver Failure (2)  ·  Pathologic Processes (2)  ·  Brain Diseases (1)  ·  Brain Diseases, Metabolic (1)  ·  Central Nervous System Diseases (1)

Interventions

Digoxin (1)  ·  S-Adenosylmethionine (1)  ·  Ursodeoxycholic Acid (1)  ·  metadoxine (1)

Sponsors

Fatty Liver and Alcoholic Liver Disease Study Group, China (1)  ·  King's College London (1)  ·  PharmaKing (1)  ·  Phenomen Pharma (1)  ·  Regeneron Pharmaceuticals (1)  ·  Universiti Kebangsaan Malaysia Medical Centre (1)  ·  Yale University (1)

Countries

China (1)  ·  Malaysia (1)  ·  Russia (1)  ·  South Korea (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Bubu Banini, MD, PhD (1)  ·  Jiangao Fan, MD (1)